Cadiatev 2 mg Prolonged-release tablets.
PDF Leaflet Revision Date: 30 October 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Short-term treatment of primary insomnia in patients aged 55 and over.
Dosage (summary)
2 mg once daily, 1-2 hours before bedtime after food.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly
Pregnancy & Breastfeeding
Safety in pregnancy and lactation not established.
Key Drug Interactions
- Fluvoxamine increases melatonin levels
- Cimetidine increases melatonin levels
- Alcohol reduces effectiveness
Contraindications
- Hypersensitivity to melatonin or excipients
- Autoimmune diseases
Common side effects
- Drowsiness
- Headache
- Dizziness
Counselling Points
- Take 1-2 hours before bedtime
- Avoid alcohol
- Not for use in children under 18
Serious warnings
- May cause drowsiness, caution when driving
- Not recommended for autoimmune diseases
Important Disclaimer
The Cadiatev 2 mg Prolonged-release tablets. professional information leaflet below is the property of Teva Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
